Please wait while the formulary information is being retrieved.
DAUNORUBICIN HCL (DAUNORUBICIN HCL)
- Acute lymphoid leukemia
- Acute monocytic leukemia
- Acute myeloid leukemia
- Acute promyelocytic leukemia
- Erythroid leukemia
5 mg/mL intravenous solution
- Dosage information is not available
daunorubicin 5 mg/mL intravenous solution
- Dosage information is not available
5 mg/mL intravenous solution
- Dosage information is not available
daunorubicin 5 mg/mL intravenous solution
- Dosage information is not available
Acute lymphoid leukemia
- Infuse 45 mg/m2 by intravenous route on days 1, 2 and 3 of a 32 day cycle
Acute monocytic leukemia
- Infuse 45 mg/m2 by intravenous route on days 1 and 2 of each course of therapy
Acute myeloid leukemia
- Infuse 45 mg/m2 by intravenous route on days 1 and 2 of each course of therapy
Acute promyelocytic leukemia
- Infuse 45 mg/m2 by intravenous route on days 1 and 2 of each course of therapy
Erythroid leukemia
- Infuse 45 mg/m2 by intravenous route on days 1 and 2 of each course of therapy
- adenovirus vac live type-4 & 7
- adenovirus vaccine live type-4
- adenovirus vaccine live type-7
- BCG vaccine, live (PF)
- flu vac,qval 2013-14 (2-49yrs)
- Flumist 2013-2014
- M-m-r Ii (pf)
- measles,mumps&rubella vacc(PF)
- measles,mumps,rub,varicel(PF)
- natalizumab
- Proquad (pf)
- Rotateq Vaccine
- rotavirus vaccine live, penta
- typhoid vaccine
- Tysabri
- varicella virus vacc live (PF)
- Varivax (pf)
- Vivotif Berna Vaccine
- yellow fever vaccine live (PF)
- Yf-vax (pf)
- Zostavax (pf)
- zoster vaccine live (PF)
Contraindicated
- ado-trastuzumab emtansine
- clozapine
- Clozaril
- deferiprone
- Fazaclo
- Ferriprox
- Herceptin
- Kadcyla
- trastuzumab
- Versacloz
Severe
Moderate
- None
- Cardiomyopathy
- Chronic heart failure
- Lactating mother
- Ventricular tachycardia
Contraindicated
- Bacterial infection
- Bone marrow depression
- Cardiac arrhythmia
- Disease of liver
- Granulocytopenic disorder
- Hyperuricemia
- Kidney disease with likely reduction in GFR
- Myocarditis
- Neutropenic disorder
- Opportunistic fungal infection
- Opportunistic viral infection
- Pericarditis
- Pregnancy
- Protozoal infection
- Seizure disorder
Severe
Moderate
- None
DAUNORUBICIN HCL (DAUNORUBICIN HCL)
- Acute lymphoid leukemia
- Acute monocytic leukemia
- Acute myeloid leukemia
- Acute promyelocytic leukemia
- Erythroid leukemia
- Esophagitis
- Infection
- Leukopenia
- Stomatitis
- Alopecia
- Nausea
- Urine discoloration
- Vomiting
More Frequent
Severe
Less Severe
- Chronic heart failure
- Gastrointestinal ulcer
- Hyperuricemia
- Injection site sequelae
- Severe bone marrow depression
- Thrombocytopenic disorder
- Tissue necrosis
- Uric acid nephropathy
- None
Less Frequent
Severe
Less Severe
Rare / Very Rare
Severe
- Allergic dermatitis
- Extravasation injury
- Myocarditis
- Pericarditis
- Pruritus of skin
- Skin rash
- Urticaria
Less Severe
- Diarrhea
- Skin thickening
Contraindicated
None
Severe Precaution
Daunorubicin
Risk of cardiotoxicity above cumulative dose 10 mg/kg
Risk of cardiotoxicity above cumulative dose 300 mg/m2
- 1 Day – 2 Years
- Risk of cardiotoxicity above cumulative dose 10 mg/kg
- Risk of cardiotoxicity above cumulative dose 300 mg/m2
- 2 Years – 13 Years
- Risk of cardiotoxicity above cumulative dose 10 mg/kg
- Risk of cardiotoxicity above cumulative dose 300 mg/m2
Management or Monitoring Precaution
None
Daunorubicin
- Severity Level:
D
- Additional Notes:
Contraindicated
Daunorubicin
Insufficient human data; potential for severe toxicity
| General | Excretion Potential | Effect on Infant | Notes |
| Drug should not be given to breast feeding mothers | Unknown | Not known; no or inclusive data | Insufficient human data; potential for severe toxicity |
Precaution Exists
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
No Known Risk
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Contraindicated
None
Precaution Exists
Daunorubicin
General-Assess bone marrow reserves in the elderly as they may be lower, thus increasing the risk of prolonged suppression. Cardiovascular-Cardiotoxicity may be more frequent in elderly. Renal-age-related renal dysfunction may require dose reduction.
| Organ / System | HEP | REN | CARD | ENDO | NEURO / PSYCH | PULM |
| Increased Risk / Adverse Effects | Y | N | Y | N | N | N |
BEERS: N HEDIS: N STOPP: N
No Known Risk
None
- Daunorubicin must be given only by injection into a vein. This medication must not be given by injection into a muscle or under the skin. If this medication accidentally leaks into the skin/muscle around the injection site, it may cause severe damage.<br /><br />Tell your doctor right away if you notice redness, pain, or swelling at or near the injection site. This medication may rarely cause serious (rarely fatal) heart problems (including heart failure). This may occur both during treatment or months to years after treatment is completed.<br /><br />The risk of heart problems is affected by your dose, medical history (including previous heart disease, radiation treatment to the chest area), and previous use of this and other drugs (including doxorubicin). Tell your doctor right away if you notice symptoms such as irregular heartbeat, shortness of breath, swelling ankles/feet, unusual tiredness, or unusual/sudden weight gain. Daunorubicin may cause certain severe blood and bone marrow disorders (low red blood cells/white blood cells/platelets).<br /><br />This can affect your body's ability to stop bleeding or fight infection. Tell your doctor right away if you develop easy bleeding/bruising or signs of infection (e.g., fever, chills, persistent sore throat). Very rarely, people with cancer who are treated with this type of medication have developed other cancers (e.g., secondary leukemia).<br /><br />The risk may be increased when this medication is given with certain anti-cancer drugs or radiation treatment. Consult your doctor for more details. Before starting treatment with this medication, tell your doctor if you have liver or kidney problems. Your dose may need to be adjusted.
| Acute lymphoid leukemia | |
| C91.0 | Acute lymphoblastic leukemia [ALl] |
| C91.00 | Acute lymphoblastic leukemia not having achieved remission |
| C91.02 | Acute lymphoblastic leukemia, in relapse |
| Acute monocytic leukemia | |
| C93.0 | Acute monoblastic/monocytic leukemia |
| C93.00 | Acute monoblastic/monocytic leukemia, not having achieved remission |
| C93.02 | Acute monoblastic/monocytic leukemia, in relapse |
| Acute myeloid leukemia | |
| C92.0 | Acute myeloblastic leukemia |
| C92.00 | Acute myeloblastic leukemia, not having achieved remission |
| C92.02 | Acute myeloblastic leukemia, in relapse |
| C92.4 | Acute promyelocytic leukemia |
| C92.40 | Acute promyelocytic leukemia, not having achieved remission |
| C92.42 | Acute promyelocytic leukemia, in relapse |
| C92.5 | Acute myelomonocytic leukemia |
| C92.50 | Acute myelomonocytic leukemia, not having achieved remission |
| C92.52 | Acute myelomonocytic leukemia, in relapse |
| C92.6 | Acute myeloid leukemia with 11q23-abnormality |
| C92.60 | Acute myeloid leukemia with 11q23-abnormality not having achieved remission |
| C92.62 | Acute myeloid leukemia with 11q23-abnormality in relapse |
| C93.0 | Acute monoblastic/monocytic leukemia |
| C93.00 | Acute monoblastic/monocytic leukemia, not having achieved remission |
| C93.02 | Acute monoblastic/monocytic leukemia, in relapse |
| C94.4 | Acute panmyelosis with myelofibrosis |
| C94.40 | Acute panmyelosis with myelofibrosis not having achieved remission |
| C94.42 | Acute panmyelosis with myelofibrosis, in relapse |
| Acute promyelocytic leukemia | |
| C92.4 | Acute promyelocytic leukemia |
| C92.40 | Acute promyelocytic leukemia, not having achieved remission |
| C92.42 | Acute promyelocytic leukemia, in relapse |
| Erythroid leukemia | |
| C94.0 | Acute erythroid leukemia |
| C94.00 | Acute erythroid leukemia, not having achieved remission |
| C94.02 | Acute erythroid leukemia, in relapse |
| 0-9 | A-Z |
|---|---|
| C91.0 | Acute lymphoblastic leukemia [ALl] |
| C91.00 | Acute lymphoblastic leukemia not having achieved remission |
| C91.02 | Acute lymphoblastic leukemia, in relapse |
| C92.0 | Acute myeloblastic leukemia |
| C92.00 | Acute myeloblastic leukemia, not having achieved remission |
| C92.02 | Acute myeloblastic leukemia, in relapse |
| C92.4 | Acute promyelocytic leukemia |
| C92.4 | Acute promyelocytic leukemia |
| C92.40 | Acute promyelocytic leukemia, not having achieved remission |
| C92.40 | Acute promyelocytic leukemia, not having achieved remission |
| C92.42 | Acute promyelocytic leukemia, in relapse |
| C92.42 | Acute promyelocytic leukemia, in relapse |
| C92.5 | Acute myelomonocytic leukemia |
| C92.50 | Acute myelomonocytic leukemia, not having achieved remission |
| C92.52 | Acute myelomonocytic leukemia, in relapse |
| C92.6 | Acute myeloid leukemia with 11q23-abnormality |
| C92.60 | Acute myeloid leukemia with 11q23-abnormality not having achieved remission |
| C92.62 | Acute myeloid leukemia with 11q23-abnormality in relapse |
| C93.0 | Acute monoblastic/monocytic leukemia |
| C93.0 | Acute monoblastic/monocytic leukemia |
| C93.00 | Acute monoblastic/monocytic leukemia, not having achieved remission |
| C93.00 | Acute monoblastic/monocytic leukemia, not having achieved remission |
| C93.02 | Acute monoblastic/monocytic leukemia, in relapse |
| C93.02 | Acute monoblastic/monocytic leukemia, in relapse |
| C94.0 | Acute erythroid leukemia |
| C94.00 | Acute erythroid leukemia, not having achieved remission |
| C94.02 | Acute erythroid leukemia, in relapse |
| C94.4 | Acute panmyelosis with myelofibrosis |
| C94.40 | Acute panmyelosis with myelofibrosis not having achieved remission |
| C94.42 | Acute panmyelosis with myelofibrosis, in relapse |
Formulary Reference Tool